Atalie C Thompson1, Alessandro A Jammal1, Felipe A Medeiros2. 1. Vision, Imaging and Performance (VIP) Laboratory, Duke Eye Center and Department of Ophthalmology, Duke University, Durham, North Carolina. 2. Vision, Imaging and Performance (VIP) Laboratory, Duke Eye Center and Department of Ophthalmology, Duke University, Durham, North Carolina. Electronic address: felipe.medeiros@duke.edu.
Abstract
PURPOSE: To evaluate whether loss of 5 μm or more in global retinal nerve fiber layer (RNFL) thickness on spectral-domain (SD) between 2 consecutive visits is specific for glaucoma progression. DESIGN: Prospective cohort. PARTICIPANTS: Ninety-two eyes of 49 control participants and 300 eyes of 210 glaucoma patients. METHODS: Patients completed at least 5 standard automated perimetry and SD OCT examinations at 6-month intervals over at least 2 years. Eyes were categorized as progressing from glaucoma if the average RNFL declined by 5 μm or more between 2 consecutive visits. The false-positive proportion was estimated by 2 methods: (1) 5-μm or more loss in control participants and (2) 5-μm or more gain in glaucoma. The false-positive proportion was subtracted from the cumulative proportion of eyes categorized with glaucoma progression to estimate the true progression prevalence. MAIN OUTCOME MEASURES: False-positive and true progression prevalence of patients with glaucoma detected as progressing on SD OCT. RESULTS: After 5 years of semiannual testing, the cumulative proportion of false-positive results based on 5-μm or more RNFL losses between visits was 24.8% in the control participants. Although 40.6% of glaucoma eyes were diagnosed with progression at 5 years, only 15.8% would have been considered to show true progression based on the expected false-positive ratio from the control participants (i.e., 40.6%-24.8%). The cumulative proportion of an intervisit gain of 5 μm or more at 5 years was 27.4% in glaucoma eyes, suggesting that only 13.2% of eyes with glaucoma truly had progressed (i.e., 40.6%-27.4%). CONCLUSIONS: Loss of 5 μm or more in average RNFL thickness between consecutive SD OCT tests is not specific for glaucoma progression. Application of this intervisit rule of 5 can result in a high cumulative proportion of false-positive results over time, which could lead to unnecessary interventions in patients whose disease is stable. More specific diagnostic criteria are needed to help clinicians determine whether patients with glaucoma are progressing so that therapy escalation is both timely and appropriate.
PURPOSE: To evaluate whether loss of 5 μm or more in global retinal nerve fiber layer (RNFL) thickness on spectral-domain (SD) between 2 consecutive visits is specific for glaucoma progression. DESIGN: Prospective cohort. PARTICIPANTS: Ninety-two eyes of 49 control participants and 300 eyes of 210 glaucomapatients. METHODS:Patients completed at least 5 standard automated perimetry and SD OCT examinations at 6-month intervals over at least 2 years. Eyes were categorized as progressing from glaucoma if the average RNFL declined by 5 μm or more between 2 consecutive visits. The false-positive proportion was estimated by 2 methods: (1) 5-μm or more loss in control participants and (2) 5-μm or more gain in glaucoma. The false-positive proportion was subtracted from the cumulative proportion of eyes categorized with glaucoma progression to estimate the true progression prevalence. MAIN OUTCOME MEASURES: False-positive and true progression prevalence of patients with glaucoma detected as progressing on SD OCT. RESULTS: After 5 years of semiannual testing, the cumulative proportion of false-positive results based on 5-μm or more RNFL losses between visits was 24.8% in the control participants. Although 40.6% of glaucoma eyes were diagnosed with progression at 5 years, only 15.8% would have been considered to show true progression based on the expected false-positive ratio from the control participants (i.e., 40.6%-24.8%). The cumulative proportion of an intervisit gain of 5 μm or more at 5 years was 27.4% in glaucoma eyes, suggesting that only 13.2% of eyes with glaucoma truly had progressed (i.e., 40.6%-27.4%). CONCLUSIONS: Loss of 5 μm or more in average RNFL thickness between consecutive SD OCT tests is not specific for glaucoma progression. Application of this intervisit rule of 5 can result in a high cumulative proportion of false-positive results over time, which could lead to unnecessary interventions in patients whose disease is stable. More specific diagnostic criteria are needed to help clinicians determine whether patients with glaucoma are progressing so that therapy escalation is both timely and appropriate.
Authors: Christopher K S Leung; Cong Ye; Robert N Weinreb; Marco Yu; Gilda Lai; Dennis S Lam Journal: Ophthalmology Date: 2013-08-30 Impact factor: 12.079
Authors: Balwantray C Chauhan; Donna M Hutchison; Paul H Artes; Joseph Caprioli; Jost B Jonas; Raymond P LeBlanc; Marcelo T Nicolela Journal: Invest Ophthalmol Vis Sci Date: 2008-12-05 Impact factor: 4.799
Authors: Christopher K S Leung; Marco Yu; Robert N Weinreb; Cong Ye; Shu Liu; Gilda Lai; Dennis S C Lam Journal: Ophthalmology Date: 2012-01-20 Impact factor: 12.079
Authors: Jean-Claude Mwanza; Robert T Chang; Donald L Budenz; Mary K Durbin; Mohamed G Gendy; Wei Shi; William J Feuer Journal: Invest Ophthalmol Vis Sci Date: 2010-06-23 Impact factor: 4.799
Authors: Pamela A Sample; Christopher A Girkin; Linda M Zangwill; Sonia Jain; Lyne Racette; Lida M Becerra; Robert N Weinreb; Felipe A Medeiros; M Roy Wilson; Julio De León-Ortega; Celso Tello; Christopher Bowd; Jeffrey M Liebmann Journal: Arch Ophthalmol Date: 2009-09
Authors: Xinbo Zhang; Brian A Francis; Anna Dastiridou; Vikas Chopra; Ou Tan; Rohit Varma; David S Greenfield; Joel S Schuman; David Huang Journal: Transl Vis Sci Technol Date: 2016-03-04 Impact factor: 3.283
Authors: Ricardo Y Abe; Alberto Diniz-Filho; Linda M Zangwill; Carolina P B Gracitelli; Amir H Marvasti; Robert N Weinreb; Saif Baig; Felipe A Medeiros Journal: Invest Ophthalmol Vis Sci Date: 2016-07-01 Impact factor: 4.799
Authors: Zhichao Wu; Denis S D Weng; Rashmi Rajshekhar; Abinaya Thenappan; Robert Ritch; Donald C Hood Journal: Transl Vis Sci Technol Date: 2018-05-01 Impact factor: 3.283
Authors: Atalie C Thompson; Alessandro A Jammal; Samuel I Berchuck; Eduardo B Mariottoni; Zhichao Wu; Fabio B Daga; Nara G Ogata; Carla N Urata; Tais Estrela; Felipe A Medeiros Journal: Ophthalmol Glaucoma Date: 2020-06-14
Authors: Zane Z Zemborain; Emmanouil Tsamis; Sol La Bruna; Ari Leshno; C Gustavo De Moraes; Robert Ritch; Donald C Hood Journal: J Glaucoma Date: 2022-03-18 Impact factor: 2.290
Authors: Abinaya Thenappan; Emmanouil Tsamis; Zane Z Zemborain; Sol La Bruna; Melvi Eguia; Devon Joiner; Carlos Gustavo De Moraes; Donald C Hood Journal: Optom Vis Sci Date: 2021-05-01 Impact factor: 2.106
Authors: Donald C Hood; Bruna Melchior; Emmanouil Tsamis; Jeffrey M Liebmann; Carlos G De Moraes Journal: J Glaucoma Date: 2021-04-01 Impact factor: 2.290
Authors: Melvi D Eguia; Emmanouil Tsamis; Zane Z Zemborain; Ashley Sun; Joseph Percival; C Gustavo De Moraes; Robert Ritch; Donald C Hood Journal: Transl Vis Sci Technol Date: 2020-10-19 Impact factor: 3.283